Meplazumab for injection
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Post-COVID-19
Conditions
Post-COVID-19
Trial Timeline
Mar 23, 2023 → Oct 26, 2023
NCT ID
NCT05813587About Meplazumab for injection
Meplazumab for injection is a phase 3 stage product being developed by Pacific Biosciences for Post-COVID-19. The current trial status is completed. This product is registered under clinical trial identifier NCT05813587. Target conditions include Post-COVID-19.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06040346 | Phase 2 | Active |
| NCT05679479 | Phase 3 | Completed |
| NCT05813587 | Phase 3 | Completed |
Competing Products
2 competing products in Post-COVID-19
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Nirmatrelvir/ritonavir + Placebo/ritonavir | Pfizer | Phase 2 | 51 |
| Vortioxetine + Placebo | Brain Biotech | Phase 2 | 44 |